Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003674 · ClinicalTrials.gov registry record · Phase 3
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT00003674 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 141 participants.
The verdict
NCT00003674, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients with advanced cancer that has not responded to previous treatment. It is not yet known if standard therapy is more effective with or without dalteparin in treating advanced breast, lung, colorectal, and prostate cancer. PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of standard therapy with or without dalteparin in treating patients who have advanced breast, lung, colorectal, or prostate cancer that has not responded to previous chemotherapy or hormone therapy.
Interventions
- DRUG dalteparin
- DRUG standard therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 1998-12 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003674
The ClinicalTrials.gov registry entry for NCT00003674 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dalteparin is the first listed.
NCT00003674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003674 about?
NCT00003674 is a clinical study titled "Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer". RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients with advanced cancer that has not responded to previous treatment. It is n...
What is the current status of trial NCT00003674?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 1998-12. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00003674?
The interventions under investigation include: dalteparin (DRUG), standard therapy (DRUG).
Who is sponsoring clinical trial NCT00003674?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.